ATE249243T1 - Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat - Google Patents
Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelatInfo
- Publication number
- ATE249243T1 ATE249243T1 AT97902867T AT97902867T ATE249243T1 AT E249243 T1 ATE249243 T1 AT E249243T1 AT 97902867 T AT97902867 T AT 97902867T AT 97902867 T AT97902867 T AT 97902867T AT E249243 T1 ATE249243 T1 AT E249243T1
- Authority
- AT
- Austria
- Prior art keywords
- chelate
- toxin
- drug
- antibodies
- net load
- Prior art date
Links
- 239000013522 chelant Substances 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003053 toxin Substances 0.000 title 1
- 231100000765 toxin Toxicity 0.000 title 1
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 2
- 238000002560 therapeutic procedure Methods 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 125000003277 amino group Chemical group 0.000 abstract 1
- 239000011616 biotin Substances 0.000 abstract 1
- 229960002685 biotin Drugs 0.000 abstract 1
- 235000020958 biotin Nutrition 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000013043 chemical agent Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000021615 conjugation Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/10—Organic compounds
- A61K49/14—Peptides, e.g. proteins
- A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
- A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2123/00—Preparations for testing in vivo
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Radiology & Medical Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US58607596A | 1996-01-11 | 1996-01-11 | |
| PCT/US1997/000307 WO1997025069A1 (en) | 1996-01-11 | 1997-01-06 | Antibodies with reduced net positive charge |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE249243T1 true ATE249243T1 (de) | 2003-09-15 |
Family
ID=24344206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT97902867T ATE249243T1 (de) | 1996-01-11 | 1997-01-06 | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0873139B1 (de) |
| JP (2) | JP2000503301A (de) |
| KR (1) | KR100485240B1 (de) |
| AT (1) | ATE249243T1 (de) |
| AU (1) | AU730388B2 (de) |
| CA (1) | CA2242750C (de) |
| DE (1) | DE69724761T2 (de) |
| ES (1) | ES2206683T3 (de) |
| RU (1) | RU2219949C2 (de) |
| WO (1) | WO1997025069A1 (de) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005047903A1 (en) * | 2003-11-07 | 2005-05-26 | Upstate Usa. Inc. | A method for generating antibody conjugates that preserves antigen recognition |
| WO2013184200A1 (en) * | 2012-06-05 | 2013-12-12 | Msm Protein Technologies | Human monoclonal antibodies against human chemokine receptor ccr7 |
| MX353951B (es) | 2012-07-04 | 2018-02-07 | Hoffmann La Roche | Anticuerpos de anti-teofilina y metodos de uso. |
| EP2870180B1 (de) | 2012-07-04 | 2024-08-28 | F. Hoffmann-La Roche AG | Anti-biotin-antikörper und verwendungsverfahren |
| JP6148729B2 (ja) | 2012-07-04 | 2017-06-14 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 共有結合している抗原−抗体結合体 |
| EP3089759B1 (de) | 2014-01-03 | 2018-12-05 | F. Hoffmann-La Roche AG | Kovalent verknüpfte polypeptidtoxin-antikörperkonjugate |
| KR20160104628A (ko) | 2014-01-03 | 2016-09-05 | 에프. 호프만-라 로슈 아게 | 이중특이성 항-합텐/항-혈액뇌장벽 수용체 항체, 그의 복합체 및 혈액뇌장벽 셔틀로서 그의 용도 |
| CN105873615B (zh) | 2014-01-03 | 2020-12-25 | 豪夫迈·罗氏有限公司 | 共价连接的helicar-抗helicar抗体缀合物及其用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4753894A (en) * | 1984-02-08 | 1988-06-28 | Cetus Corporation | Monoclonal anti-human breast cancer antibodies |
| FR2566271B1 (fr) * | 1984-06-20 | 1986-11-07 | Sanofi Sa | Nouveaux conjugues cytotoxiques utilisables en therapeutique et procede d'obtention |
| WO1988007553A1 (fr) * | 1987-03-26 | 1988-10-06 | Teijin Limited | Procede de preparation d'un complexe d'anticorps |
| WO1991007991A1 (en) * | 1989-11-30 | 1991-06-13 | Mallinckrodt Medical, Inc. | Method for preparing a metal-radionuclide-labelled protein |
| US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| SE9100142L (sv) * | 1991-01-17 | 1992-07-18 | Bengt Sandberg | En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal |
| JPH07507804A (ja) * | 1992-06-09 | 1995-08-31 | ネオルックス コーポレーション | 予備標的化方法及び化合物 |
| US5578287A (en) * | 1992-06-09 | 1996-11-26 | Neorx Corporation | Three-step pretargeting methods using improved biotin-active agent |
| JPH0853499A (ja) * | 1994-08-10 | 1996-02-27 | Green Cross Corp:The | キメラ抗体Ｆａｂ断片のオリゴマー体 |
-
1997
- 1997-01-06 AT AT97902867T patent/ATE249243T1/de active
- 1997-01-06 EP EP97902867A patent/EP0873139B1/de not_active Expired - Lifetime
- 1997-01-06 CA CA002242750A patent/CA2242750C/en not_active Expired - Fee Related
- 1997-01-06 AU AU16939/97A patent/AU730388B2/en not_active Ceased
- 1997-01-06 JP JP9525384A patent/JP2000503301A/ja active Pending
- 1997-01-06 RU RU98115277/15A patent/RU2219949C2/ru not_active IP Right Cessation
- 1997-01-06 WO PCT/US1997/000307 patent/WO1997025069A1/en not_active Ceased
- 1997-01-06 DE DE69724761T patent/DE69724761T2/de not_active Expired - Lifetime
- 1997-01-06 ES ES97902867T patent/ES2206683T3/es not_active Expired - Lifetime
- 1997-01-06 KR KR1019980705339A patent/KR100485240B1/ko not_active Expired - Fee Related
-
2012
- 2012-02-08 JP JP2012024825A patent/JP2012131808A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69724761T2 (de) | 2004-08-05 |
| EP0873139A1 (de) | 1998-10-28 |
| WO1997025069A1 (en) | 1997-07-17 |
| KR100485240B1 (ko) | 2006-10-24 |
| CA2242750C (en) | 2007-03-27 |
| ES2206683T3 (es) | 2004-05-16 |
| RU2219949C2 (ru) | 2003-12-27 |
| AU1693997A (en) | 1997-08-01 |
| JP2000503301A (ja) | 2000-03-21 |
| AU730388B2 (en) | 2001-03-08 |
| KR19990077198A (ko) | 1999-10-25 |
| EP0873139B1 (de) | 2003-09-10 |
| DE69724761D1 (de) | 2003-10-16 |
| JP2012131808A (ja) | 2012-07-12 |
| CA2242750A1 (en) | 1997-07-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2090700A1 (en) | Modified antibodies with controlled clearance time | |
| UA66857C2 (uk) | КОН'ЮГАТ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН, СПОСІБ ОДЕРЖАННЯ КОН'ЮГАТУ ПОЛІОЛ-<font face="Symbol">b</font>-ІНТЕРФЕРОН ТА СПОСІБ ЛІКУВАННЯ ІНФЕКЦІЙНИХ ХВОРОБ, ПУХЛИН І АУТОІМУННИХ І ЗАПАЛЬНИХ ЗАХВОРЮВАНЬ | |
| ATE347378T1 (de) | Konjugate zur behandlung von entzündungskrankheiten und von assozierter gewebeschädigung | |
| ATE383430T1 (de) | Rekombinante antikörper und immunkonjugate gezielt auf cd22-tragende zellen und tumoren | |
| EP0329184A3 (de) | Antimere und antimere Konjugation | |
| NO901986L (no) | Nytt antistoff-leveringssystem for biologisk respons-modifiserende midler. | |
| CY1111863T1 (el) | Αντισωματα εναντιον υποδοχεα θανατου 4 (dr4) και χρησεις αυτων | |
| BR0015506A (pt) | Conjugados de interferon gama, métodos para sua preparação, composições farmacêuticas que compreendem ás moléculas e seu uso no tratamento de doenças | |
| EE05212B1 (et) | Polpeptiidi kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on m?eldud kasvajaraku raviks, mis ekspresseerib APRIL-i | |
| BR0016339A (pt) | Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto | |
| NO20010021L (no) | Trifunksjonelt reagens for konjugering til et biomolekyl | |
| DE60113445D1 (de) | Substanzen mit verzweigten linkermolekülen | |
| ATE249243T1 (de) | Biotinylierter antikörper mit verminderter positiver nettoladung und toxin, medikament oder chelat | |
| ATE192047T1 (de) | Bicylclische, polyazamakrocyclocarbonsäure- komplexe, konjugate, herstellung und verwendung als kontraststoffe | |
| DK0478631T3 (da) | Målsøgende midler | |
| DK0570575T3 (da) | Bicykloazamakrocyklophosphonsyre, komplekser, konjugater, kontrastmidler og fremstilling heraf | |
| FI933506A0 (fi) | Bicyklopolyazamakrocyklokarboxylsyrakomplex, konjugat daerav, foerfarande foer deras framstaellning och anvaendning som kontrastmedel | |
| BR9913429A (pt) | Anticorpos bifuncionais e seu uso na objetivação de agentes antitumor | |
| BR9714945A (pt) | Composição topicamente aplicável para introdução de fármacos peptidaceosos em organismos vivos | |
| NO954442L (no) | Bicyklopolyazamakrocyklofosfonsyrer, deres komplekser og konjugater, for anvendelse som kontrastmidler, og fremgangsmåter for deres fremstilling | |
| TR199700842T1 (xx) | �nsan DNase I Varyantlar�. | |
| Muzykantov | Conjugation of catalase to a carrier antibody via a streptavidinŐbiotin cross‐linker | |
| RU93053897A (ru) | Комплексы бициклополиазамакроциклокарбоновых кислот, их конъюгаты, фармацевтическая композиция, способ диагностики, набор и способ получения | |
| WO1998051792A8 (en) | Fac molecules and uses thereof | |
| MY109649A (en) | Bicyclopol yazamacrocyclocarboxylic acid complexes, and conjugates, processes for their prepration, and use as contrast agents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 0873139 Country of ref document: EP |